Gamma-glutamyltransferase predicts increased risk of mortality: A systematic review and meta-analysis of prospective observational studies

References

• Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001;38:263–355.
   PubMed Web of Science ®Google Scholar
• Ando K, Fujita T. Metabolic syndrome and oxidative stress. Free Radic Biol Med 2009;47:213–218.
   PubMed Web of Science ®Google Scholar
• Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599–622.
   PubMed Web of Science ®Google Scholar
• Liu CF, Gu YT, Wang HY, Fang NY. Gamma-glutamyltransferase level and risk of hypertension: a systematic review and meta-analysis. PLoS One 2012;7:e48878.
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked?Free Radic Biol Med 2010;49:1603–1616.
   PubMed Web of Science ®Google Scholar
• Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108:1912–1916.
   PubMed Web of Science ®Google Scholar
• Lee DH, Ha MH, Kam S, Chun B, Lee J, Song K, et al. A strong secular trend in serum gamma-glutamyltransferase from 1996 to 2003 among South Korean men. Am J Epidemiol 2006;163:57–65.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–2012.
   Google Scholar
• Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301–1309.
   PubMed Web of Science ®Google Scholar
• Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012;175:66–73.
   PubMed Web of Science ®Google Scholar
• Koehler EM, Sanna D, Hansen BE, van Rooij FJ, Heeringa J, Hofman A, et al. Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver Int 2014; 34:296–304.
   PubMed Web of Science ®Google Scholar
• Loomba R, Doycheva I, Bettencourt R, Cohen B, Wassel CL, Brenner D, Barrett-Connor E. Serum gamma-glutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults. J Clin Exp Hepatol 2013;3:4–11.
   PubMedGoogle Scholar
• Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol 2012; 57:1083–1089.
   PubMed Web of Science ®Google Scholar
• Breitling LP, Claessen H, Drath C, Arndt V, Brenner H. Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years. J Hepatol 2011;55:594–601.
   PubMed Web of Science ®Google Scholar
• Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011;54: 145–152.
   PubMed Web of Science ®Google Scholar
• Loh WJ, North BV, Johnston DG, Godsland IF. Insulin resistance-related biomarker clustering and subclinical inflammation as predictors of cancer mortality during 21.5 years of follow-up. Cancer Causes Control 2010;21:709–718.
   PubMed Web of Science ®Google Scholar
• Fujiyoshi A, Miura K, Hozawa A, Murakami Y, Takashima N, Okuda N, et al. γ-Glutamyltransferase and mortality risk from heart disease and stroke in Japanese men and women: NIPPON DATA90. CVD Prevention and Control 2010;5: 27–34.
   Google Scholar
• Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009;50:1403–1411.
   PubMed Web of Science ®Google Scholar
• Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009;136: 477–485 e11.
   PubMed Web of Science ®Google Scholar
• Lee DH, Buijsse B, Steffen L, Holtzman J, Luepker R, Jacobs DR, Jr. Association between serum gamma- glutamyltransferase and cardiovascular mortality varies by age: the Minnesota Heart Survey. Eur J Cardiovasc Prev Rehabil 2009;16:16–20.
   PubMedGoogle Scholar
• Strasak AM, Kelleher CC, Klenk J, Brant LJ, Ruttmann E, Rapp K, et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Thromb Vasc Biol 2008;28:1857–1865.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008;201:168–175.
   PubMed Web of Science ®Google Scholar
• Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007;27: 127–133.
   PubMed Web of Science ®Google Scholar
• Lee DH, Silventoinen K, Hu G, Jacobs DR, Jr., Jousilahti P, Sundvall J, Tuomilehto J. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 2006;27:2170–2176.
   PubMed Web of Science ®Google Scholar
• Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H, Vorarlberg Health M, Promotion Program Study G. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130–2137.
   PubMed Web of Science ®Google Scholar
• Ulmer H, Kelleher C, Diem G, Concin H. Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J Womens Health (Larchmt) 2004;13:41–53.
   PubMed Web of Science ®Google Scholar
• Wannamethee G, Ebrahim S, Shaper AG. Gamma- glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995;142:699–708.
   PubMed Web of Science ®Google Scholar
• Aksakal E, Tanboga IH, Kurt M, Kaygin MA, Kaya A, Isik T, et al. The relation of serum gamma-glutamyl transferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis 2012;221:596–601.
   PubMed Web of Science ®Google Scholar
• Bode E, Wuppinger T, Bode T, Alber H, Ulmer H, Pachinger O, Mair J. Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors. Coron Artery Dis 2012;23:91–97.
   PubMed Web of Science ®Google Scholar
• Ozcan F, Karakas MF, Ozlu MF, Akcay AB, Buyukkaya E, Kurt M, et al. Effect of serum gamma-glutamyl transferase levels on myocardial perfusion and long-term prognosis after primary angioplasty in patients with acute ST-elevation myocardial infarction. J Investig Med 2012;60:1186–1193.
   PubMed Web of Science ®Google Scholar
• Breitling LP, Grandi NC, Hahmann H, Wusten B, Rothenbacher D, Brenner H. Gamma-glutamyltransferase and prognosis in patients with stable coronary heart disease followed over 8 years. Atherosclerosis 2010;210: 649–655.
   PubMed Web of Science ®Google Scholar
• Stojakovic T, Scharnagl H, Trauner M, Pieske B, Wellnitz B, Seelhorst U, et al. Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 2010;208:564–571.
   PubMed Web of Science ®Google Scholar
• Emdin M, Passino C, Michelassi C, Donato L, Pompella A, Paolicchi A. Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol 2009; 136:80–85.
   PubMed Web of Science ®Google Scholar
• Emdin M, Passino C, Michelassi C, Titta F, L’Abbate A, Donato L, et al. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J 2001;22:1802–1807.
   PubMed Web of Science ®Google Scholar
• Karlson BW, Lindqvist J, Sjolin M, Caidahl K, Herlitz J. Which factors determine the long-term outcome among patients with a very small or unconfirmed AMI. Int J Cardiol 2001;78:265–275.
   PubMed Web of Science ®Google Scholar
• Sluik D, Beulens JW, Weikert C, van Dieren S, Spijkerman AM, van der AD, et al. Gamma-glutamyltransferase, cardiovascular disease and mortality in individuals with diabetes mellitus. Diabetes Metab Res Rev 2012;28:284–288.
   PubMed Web of Science ®Google Scholar
• Monami M, Balzi D, Lamanna C, Melani C, Cocca C, Lotti E, et al. Prognostic value of serum liver enzymes levels in type 2 diabetic patients. Diabetes Metab Res Rev 2007; 23:625–630.
   PubMed Web of Science ®Google Scholar
• Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and long-term survival: is it just the liver?Clin Chem 2007;53: 940–946.
   PubMed Web of Science ®Google Scholar
• Edlinger M, Concin N, Concin H, Nagel G, Ulmer H, Gobel G. Lifestyle-related biomarkers and endometrial cancer survival: elevated gamma-glutamyltransferase as an important risk factor. Cancer Epidemiol 2013;37:156–161.
   PubMed Web of Science ®Google Scholar
• Talsnes O, Hjelmstedt F, Dahl OE, Pripp AH, Reikeras O. Biochemical lung, liver and kidney markers and early death among elderly following hip fracture. Arch Orthop Trauma Surg 2012;132:1753–1758.
   PubMed Web of Science ®Google Scholar
• Zelle DM, Corpeleijn E, van Ree RM, Stolk RP, van der Veer E, Gans RO, et al. Markers of the hepatic component of the metabolic syndrome as predictors of mortality in renal transplant recipients. Am J Transplant 2010;10:106–114.
   PubMedGoogle Scholar
• Thomson SJ, Cowan ML, Johnston I, Musa S, Grounds M, Rahman TM. ’Liver function tests’ on the intensive care unit: a prospective, observational study. Intensive Care Med 2009;35:1406–1411.
   PubMed Web of Science ®Google Scholar
• Fraser A, Thinggaard M, Christensen K, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int 2009;29:1494–1499.
   PubMed Web of Science ®Google Scholar
• Postorino M, Marino C, Tripepi G, Zoccali C. Gammaglutamyltransferase in ESRD as a predictor of all-cause and cardiovascular mortality: another facet of oxidative stress burden. Kidney Int Suppl 2008;(111):S64–S66.
   PubMedGoogle Scholar
• Nilsson SE, Evrin PE, Tryding N, Berg S, McClearn G, Johansson B. Biochemical values in persons older than 82 years of age: report from a population-based study of twins. Scand J Clin Lab Invest 2003;63:1–13.
   PubMed Web of Science ®Google Scholar
• Du G, Song Z, Zhang Q. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med 2013; 57:31–37.
   PubMed Web of Science ®Google Scholar
• Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362: 1563–1574.
   PubMed Web of Science ®Google Scholar
• , Action to Control Cardiovascular Risk in Diabetes Study GGerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545–2559.
   PubMed Web of Science ®Google Scholar
• Group AS, Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008;371:1800–1809.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K–34K.
   PubMed Web of Science ®Google Scholar
• Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891.
   PubMedGoogle Scholar
• Iciek M, Chwatko G, Rokita H, Bald E, Wlodek L. The effects of modulation of gamma-glutamyl transpeptidase activity in HepG2 cells on thiol homeostasis and caspase-3-activity. Biochim Biophys Acta 2007;1773:201–208.
   PubMed Web of Science ®Google Scholar
• Niida S, Kawahara M, Ishizuka Y, Ikeda Y, Kondo T, Hibi T, et al. Gamma-glutamyltranspeptidase stimulates receptor activator of nuclear factor-kappaB ligand expression independent of its enzymatic activity and serves as a pathological bone-resorbing factor. J Biol Chem 2004;279: 5752–5756.
   PubMed Web of Science ®Google Scholar